As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Various infectious vesicular diseases, such as foot-and-mouth disease ... Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...